# Faricimab

## Vabysmo intravitreal inj 6mg/0.05mL

##### 臨採

| TAH Drug Code      | [IVAB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IVAB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months), but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals, up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash, itching, urticaria, erythema, or severe intraocular inflammation).                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%), Raised intraocular pressure (3-4%), Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Vabysmo intravitreal inj 6mg/0.05mL(Sample)

##### 臨採

| TAH Drug Code      | [IVAB0](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IVAB0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months), but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals, up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash, itching, urticaria, erythema, or severe intraocular inflammation).                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%), Raised intraocular pressure (3-4%), Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

